Overview

* Galectin Therapeutics ( GALT ) Q3 net loss narrows to $8.2 mln from $11.2 mln last year

* Operating expenses for Q3 decrease due to NAVIGATE trial conclusion

* Company has $11.5 mln cash and $10 mln credit line to fund operations through June 2026

Outlook

* Galectin expects FDA feedback on NAVIGATE data by year-end

* Company focuses on advancing FDA dialogue for belapectin

* Galectin exploring strategic opportunities for belapectin program

Result Drivers

* Research and development expenses for the quarter ended September 30, 2025 were $2.6 million compared with $7.6 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.13

Q3 Net -$8.18

Income mln

Q3 $4.20

Operatin mln

g

Expenses

Q3 -$4.20

Operatin mln

g Income

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Galectin Therapeutics Inc ( GALT ) is $6.00, about 7.8% above its November 13 closing price of $5.53

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)